EUVIMEDEUVIMED entdecken
Crossref

Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib

Likun Liuone

Open Journal of Clinical and Medical Case Reports · 2023

DOI: 10.52768/2379-1039/1969 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Journal of Clinical and Medical Case Reports, 2023. Verfasst von Likun Liuone.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary Sarcomatoid Carcinoma (PSC) is a rare and highly malignant subtype of Non Small Cell Lung Cancer (NSCLC). In contrast to other types of lung cancers, recent retrospective studies demonstrated that PSC always shows frequent genetic mutations, high TMB and high PD L1 expression which indicates these patients might derive survival benefits from immune checkpoint inhibitors

Zitieren

APA

Liuone, L. (2023). Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib. Open Journal of Clinical and Medical Case Reports. https://doi.org/10.52768/2379-1039/1969

Vancouver

Liuone L. Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib. Open Journal of Clinical and Medical Case Reports. 2023. doi:10.52768/2379-1039/1969

BibTeX
@article{Liuone2023,
  author = {Liuone, Likun},
  title = {Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib},
  journal = {Open Journal of Clinical and Medical Case Reports},
  year = {2023},
  doi = {10.52768/2379-1039/1969}
}
Kostenlos starten →